FDA Recalls Methylcobalamin Due to Missing Stability Data
American Pharmaceutical Ingredients LLC is recalling Methylcobalamin (Vitamin B12) for prescription compounding because the manufacturer lacked stability data to support the assigned expiration dates.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this as a Class II recall. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), particularly when involving significant regulatory deviations like missing stability data that could impact product safety.
Plain-English summary
The U.S. Food and Drug Administration (FDA) has issued a Class II recall for Methylcobalamin (Vitamin B12) intended for prescription compounding. The product is manufactured by American Pharmaceutical Ingredients LLC and is available in various package sizes, including 500mg, 1g, 5g, 10g, 25g, and 100g. The recall covers approximately 10,769 grams of the product distributed nationwide within the United States.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the manufacturer lacked the necessary stability data and controls to support the retest or expiration dates assigned to the product in its container/closure system. This deficiency means the assigned expiration dates may not be valid.
Healthcare professionals and pharmacies should stop using the affected lots immediately. Consumers who have purchased this product should contact their healthcare provider or pharmacist for guidance on whether to discontinue use. The affected lots include specific expiration dates ranging from 2019 to 2021, as detailed in the recall notice.
The recalled product
- Product
- Methylcobalamin (Vitamin B12) for prescription compounding, packaged in a) 500mg (NDC 58597-8142-1); b) 1g (NDC 58597-8056-2); c) 5g (NDC 58597-8056-3); d) 10g (NDC 58597-8056-4), e) 25 g (NDC 58597-8056-4); f) 100g (NDC 58597-8056-6), RX only, packed by American Pharmaceutical I
- Manufacturer
- American Pharmaceutical Ingredients LLC
- Category
- Drug — Pharmaceutical Ingredient
- Affected units
- 10,769
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (15)
- Lot #: a) b) 012216-1
- Exp. 12/31/2019
- 051515-3
- Exp. 02/28/2019
- c) 012216-1
- Exp. 02/28/2019 d) 012216-1
- 051515-2
- 061516-1
- Exp. 01/31/2020
- e) 051515-2
- exp. 02/28/2019
- 082117A-1
- Exp. 05/31/2021
- f) 012216-1
- 051515-1
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 66 recalled by American Pharmaceutical Ingredients LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 66 products in this recall →Related recalls
Same manufacturer · American Pharmaceutical Ingredients LLC
See all →- ModerateAmerican Pharmaceutical Ingredients Recalls Sermorelin Acetate Powder Due to Stability Data
FDA (Drugs) · 2018-03-21
- ModerateOxytocin USP Powder Recalled Due to Insufficient Stability Data
FDA (Drugs) · 2018-03-21
- ModerateFDA Recalls Testosterone Cypionate Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
- ModerateLevofloxacin Hemihydrate Recalled for Lack of Stability Data
FDA (Drugs) · 2018-02-28
- ModerateFDA Recalls Doxycycline Hyclate Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
Same hazard · stability data missing
See all →- ModerateLidocaine Ointment USP Recalled Due to Manufacturing Process Deviations
FDA (Drugs) · 2023-06-07
- ModerateTriamcinolone Acetonide Cream USP 0.1% Recall — Stability Study Discontinuation
FDA (Drugs) · 2022-03-30
- ModeratePentoxifylline USP Recalled Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
- ModerateFlurbiprofen USP Recalled Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
- ModerateFluconazole USP Recalled for Lack of Stability Data and Controls
FDA (Drugs) · 2018-02-28